Compare Brevis (BREV) vs Mira (MIRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brevis vs Mira — how do they compare? Brevis trades at Rp1,184 (market cap Rp294,74M, Rp183,48M 24h volume), while Mira trades at Rp700.16 (market cap Rp226,43M, Rp101,47M 24h volume). The key difference: Brevis is the larger of the two by market cap, and Brevis's circulating supply is 250M / 1B BREV (25%) versus 321,5M / 1B MIRA (33%) for Mira. Which is the better fit depends on your goals — on Pluang, investors hold Brevis for 8 Days and Mira for 22 Days on average.
| BREV | MIRA | |
|---|---|---|
Market Cap | Rp294,74M | Rp226,43M |
Volume (24h) | Rp183,48M | Rp101,47M |
Circulating Supply | 250M / 1B BREV (25%) | 321,5M / 1B MIRA (33%) |
Typical Hold Time | 8 Days | 22 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brevis (BREV) is trading at Rp1,215.88 with a market cap of Rp304.38 million, showing a bearish technical signal as moving averages indicate strong selling pressure while oscillators remain neutral. The current price sits just below the pivot point of Rp1,219, with immediate support at Rp1,203 and resistance at Rp1,237. No recent protocol updates or ecosystem news are available, and the token has a low circulation rate of 25% with a max supply of 1 million tokens.
Overall outlook is cautious due to bearish technicals and limited liquidity. Key opportunities include potential rebounds from oversold RSI levels, but major risks involve low trading volume, high volatility, and lack of recent development activity, making it susceptible to price swings.
MIRA token trades at Rp724 with bearish technical signals as moving averages indicate strong selling pressure. The token shows neutral oscillators but faces resistance at Rp726-758 levels. With 33% circulating supply and 22-day average hold time, market participation remains limited. Recent ecosystem developments show progress in pharmaceutical research applications, though direct token utility updates are scarce.
Overall outlook remains cautious due to technical bearishness and limited trading volume. Key opportunity lies in potential protocol adoption from pharmaceutical research partnerships. Major risks include low liquidity, high volatility, and regulatory uncertainty surrounding crypto-pharma intersections. Investors should monitor exchange listings and token utility expansion.
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Brevis
Brevis is a verifiable computing platform that enables scalable, trustless computation across blockchain, data, and AI systems. It allows complex programs and data queries to run off-chain and be verified on-chain using zero-knowledge proofs, delivering significantly lower costs and latency while preserving security and trustlessness.
Read more on BREV →About Mira
Mira is a decentralized verification network that enables autonomous AI by eliminating human oversight. Using consensus-based verification across multiple AI models, Mira delivers mathematically verifiable and trustless results in real time. This ensures accuracy and reliability for critical fields like healthcare, finance, and law—transforming AI from a supervised tool into truly independent intelligence.
Read more on MIRA →
